Drug
Lecanemab clinical trials
Also written BAN2401.
- studies test it
- 12
- open now
- 3
- in phase 3
- 4
- first study started
- 2012
Keep track of what changes. Save the lecanemab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 3
- Phase 2
- 2
- Phase 3
- 4
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 6
Eisai Inc. (5) · Washington University School of Medicine (2) · Ali Rezai (1) · Eisai Co., Ltd. (1) · Yonsei University (1) · The Fourth Affiliated Hospital of Zhejiang University School of Medicine (1) · First Affiliated Hospital of Wenzhou Medical University (1)
Often tested with
Tested in the same studies.
Gantenerumab (1) · Solanezumab (1) · Etalanetug (1) · Aducanumab (1)
Studies
Open first, then newest update. How each study uses lecanemab is read from its arms, and is right about nine times in ten.
Testing it · 12
- Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's BiomarkersRecruitingPhase 4The Fourth Affiliated Hospital of Zhejiang University School of MedicineNCT07688460Written as Lecanemab
- Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics ApproachsRecruitingPhase 4First Affiliated Hospital of Wenzhou Medical UniversityNCT07604896Written as Lecanemab 10 mg/kg
- Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD PathologyNot yet recruitingNot applicableYonsei UniversityNCT07544953Written as Lecanemab
- A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseActive, not recruitingPhase 3Eisai Inc.NCT03887455Written as Lecanemab IV
- DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's DiseaseActive, not recruitingPhase 3Washington University School of MedicineNCT06384573Written as lecanemab
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001Active, not recruitingPhase 2/3Washington University School of MedicineNCT01760005Written as Lecanemab
- AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate AmyloidActive, not recruitingPhase 3Eisai Inc.NCT04468659Written as Lecanemab
- A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's DiseaseCompletedPhase 2Eisai Inc.NCT01767311Written as Lecanemab 2.5 mg/kg
- Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) TherapyActive, not recruitingEarly Phase 1Ali RezaiNCT05469009Written as Lecanemab
- A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy ParticipantsCompletedPhase 1Eisai Inc.NCT05533801Written as Lecanemab
- A Study of Subcutaneous Lecanemab in Healthy ParticipantsCompletedPhase 1Eisai Inc.NCT05045716Written as Lecanemab
- A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's DiseaseCompletedPhase 1Eisai Co., Ltd.NCT02094729Written as BAN2401 2.5 mg/kg
Given in every arm · 4 — lecanemab is usual care beside what is tested
- The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.Not yet recruitingPhase 2Neurology Office of South FloridaNCT07212062Written as Lecanemab 10 mg/kg
- Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)RecruitingPhase 3Zhejiang Provincial People's HospitalNCT06530732Written as Lecanemab
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)Active, not recruitingPhase 2/3Washington University School of MedicineNCT05269394Written as Lecanemab
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseaseActive, not recruitingPhase 2Eisai Inc.NCT06602258Written as Lecanemab
As the comparator · 1 — what is tested is compared with lecanemab
Codes
What other systems call lecanemab · ClinicalTrials.gg INT000561
- MeSH (NLM) C000612089lecanemabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 12PYH0FTU9LECANEMABConfirmed FDA, NLM, Wikidata
- Wikidata Q56274769lecanemabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175105LecanemabOne source FDA
- DrugBank DB14580One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000612089 | lecanemab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 12PYH0FTU9 | LECANEMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q56274769 | lecanemab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175105 | Lecanemab | One source FDA |
| DrugBank | DB14580 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.